|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||5.25 - 5.82|
|52 Week Range||1.64 - 6.75|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.75|
Melt Pharmaceuticals, Inc., a specialty pharmaceutical company recently deconsolidated from Harrow Health, Inc. (HROW), today announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations. U.S. Patents 10,166,240 and 10,179,136 relate to methods of use, formulation compositions and methods to manufacture the same, which the company intends to commercialize through its MELT-100 program and other planned drug development initiatives. Both new patents have expiration dates in 2036. Melt Pharmaceuticals, Inc., is a development stage specialty pharmaceutical company focused on the development and commercialization of patented non-opioid and non-intravenous (or non-IV) sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Melt intends to seek regulatory approval through the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway for these proprietary technologies. Melt’s core technology is a series of combination non-opioid sedation drug formulations that may replace or supplement current sedation modalities for more than 100 million medical procedures in the United States.
SAN DIEGO, Feb. 07, 2019 -- Harrow Health, Inc. (NASDAQ: HROW), today announced that its subsidiary, Mayfield Pharmaceuticals, Inc., has acquired drug formulation assets and.
Concurrent with the financing, Greg Madison has been hired as CEO of Melt Pharmaceuticals. Most recently, Mr. Madison was CEO of Keryx Biopharmaceuticals where he led the company’s transformation from development stage to a fully integrated 200+ employee commercial organization and drove impressive revenue growth by expanding the label for the company’s lead product. Before Keryx, he was Chief Commercial Officer at specialty pharma company AMAG Pharmaceuticals and spent 12 years at Genzyme/Sanofi, ending as Vice-President and General Manager of the Renal division.
Mark L. Baum, CEO of Harrow Health, stated, “Our new name reflects our business model of creating, investing in, operating and growing a diversified portfolio of healthcare businesses that meet the needs of healthcare providers and patients across America. Harrow Health’s businesses and subsidiaries each have strong brand equity and will continue to operate under the Harrow Health corporate umbrella using their existing names. This includes Harrow Health’s wholly-owned subsidiaries ImprimisRx, the nation’s leading ophthalmology pharmaceutical compounding business, and Park Compounding.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CORAL GABLES, FL / ACCESSWIRE / November 19, 2018 / Healthcare stocks have rallied during the last 3 trading sessions. On Friday, the market powered higher, lead by healthcare stocks. Furthermore, the idea that a split congress could be a good thing for healthcare stocks is offering a brighter outlook for some investors to look closer at several smaller healthcare companies that could be set to rebound.
CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / The healthcare sector is the sector of the economy made up of companies that specialize in products and services related to health and medical care. As the industry continues to emerge as a leading place for investors to hedge against broader market volatility, companies like Premier Health Group, Inc. (PHGRF) (PHGI), ReShape Lifesciences Inc. (RSLS), Teladoc (TDOC), and Imprimis Pharmaceuticals, Inc. (IMMY). Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry.
The San Diego-based company said it had a loss of 12 cents per share. The pharmaceutical and drug compounding company posted revenue of $10.7 million in the period. In the final minutes of trading on Tuesday, ...
Since the financial collapse, the Federal Reserve — and then other nations’ central banks — took off monetary policy to make sure there wasn’t a massive global financial collapse. Interest rates are rising again and now portfolio managers are reallocating assets across stocks and bonds. Imprimis Pharmaceuticals (NASDAQ:IMMY) is a San Diego-based pharmaceutical company that specializes in compounded pharmaceuticals.
On a per-share basis, the San Diego-based company said it had net income of 12 cents. The pharmaceutical and drug compounding company posted revenue of $10.4 million in the period. In the final minutes ...
SAN DIEGO , Aug. 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the second quarter 2018. Notable Highlights from the Second Quarter of 2018: Revenues of ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern ...
Study to assess drug safety, patient preference and pharmacoeconomic measures in 200 routine cataract surgeries SAN DIEGO , Aug. 1, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) through ...
SAN DIEGO , July 18, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum ...
SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery in January 2018, which followed 483 eyes with glaucoma that were undergoing cataract surgery with concomitant trabecular microbypass stent insertion. The study was initially presented at the American Society of Cataract and Refractive Surgery (ASCRS) and examines post-surgery outcomes for patients receiving an intravitreal injection of steroid and antibiotics at the time of surgery compared with a standard drop regimen following surgery. All study participants were diagnosed with primary open-angle glaucoma and received a glaucoma stent at the time of surgery in parallel with the cataract surgery procedure. The study group of 234 eyes received an intravitreal injection (pars plana) of 0.2 mL of Dropless®, a combination of steroid and antibiotics, at the time of surgery. The control group of 249 eyes received a standard topical regimen postoperatively.
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EBS as the Company's latest news hit the wire. On May 24, 2018, the Company announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has provided up to $25 million to the Company and Profectus BioSciences, Inc. ("Profectus") to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock. Active-Investors.com is currently working on the research report for Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which also belongs to the Healthcare sector as the Company Emergent BioSolutions.